Neuroscience and Behavioral Physiology

, Volume 37, Issue 4, pp 419–424

Coaxil (tianeptine) in the treatment of depression in Parkinson’s disease

  • O. S. Levin

DOI: 10.1007/s11055-007-0029-0

Cite this article as:
Levin, O.S. Neurosci Behav Physiol (2007) 37: 419. doi:10.1007/s11055-007-0029-0


An open, non-comparative clinical study was performed to assess the efficacy and safety of tianeptine (Coaxil) in Parkinson’s disease (PD). A total of 18 patients with PD were used whose clinical state increased moderately severe and more profound depression (assessed on the Hamilton and Beck scales). After three months of treatment, depression on the Hamilton depression scale was decreased by 34% and on the Beck scale by 31% compared with baseline data (p < 0.05). Improvements in mental status were noted in 14 of 18 patients (77%); eight patients (44%) showed more than 50% reductions on the Hamilton scale. Analysis of the structure of depressive symptomatology showed that improvement occurred because of decreases in anxiety and the severity of somatoform symptoms and, to a lesser extent, in melancholy and sleep disturbance. There was no significant change in apathy. The decrease in the severity of depression was accompanied by an improvement in the quality of life. The efficacy of Coaxil was greater in patients with less marked depressive and motor symptoms, shorter durations of illness, and less marked cognitive impairments. Coaxil was well tolerated by the patients. The data obtained here provide grounds for recommending the use of Coaxil in the treatment of depression in PD.

Key words

Parkinson’s disease tianeptine depression 

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • O. S. Levin
    • 1
    • 2
  1. 1.Department of NeurologyRussian Medical Academy of Postgraduate EducationRussia
  2. 2.Center for Extrapyramidal DiseasesFederal Health AgencyMoscow